Source: ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Deirdre M.H.J. ten Berge, Daniel P. Hurkmans, Ilse den Besten, Jeroen S. Kloover, Ron H.J. Mathijssen, Reno J.E.M.A. Debets, Egbert F. Smit, Joachim G.J.V. Aerts. Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019

Member's Comments

No comment yet.

Related content which might interest you: Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004 Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center. Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology Year: 2019 PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Identification of predictive biomarkers of immunotherapy response in non-small cell lung cancer by multiparametric analysis Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Source: Eur Respir J 2007; 29: 128-133 Year: 2007 Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis Source: International Congress 2015 – Quality management in lung cancer Year: 2015 COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology Source: Eur Respir Rev 2014; 23: 92-105 Year: 2014 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Survival and prognostic factors of oligometastatic non-small cell lung carcinoma: A single center experience Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 The evaluation of surgical results in pT0-pT1 non-small cell lung carcinoma after induction therapy Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 T790M-mutation in EGFR progressive non-small cell lung cancer, role of re-biopsy and ctDNA analysis Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 Could 18F-FDG PET repeated within cycle 1 predicts objective response to chemotherapy in advanced non-small cell lung cancer (NSCLC)? A pilot study results Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer Source: Eur Respir J 2015; 46: 1762-1772 Year: 2015